Tenofovir disoproxil aspartate

Drug Profile

Tenofovir disoproxil aspartate

Alternative Names: CKD-390

Latest Information Update: 23 Jun 2016

Price : $50

At a glance

  • Originator Chong Kun Dang
  • Class Antiretrovirals; Antivirals; Phosphonic acids; Purines; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Hepatitis B

Most Recent Events

  • 01 Apr 2016 Phase-III clinical trials in Hepatitis B treatment in South Korea (PO) (NCT02805738)
  • 01 Dec 2015 Chong Kun Dang completes a phase I trial in Hepatitis B (In volunteers) in South Korea (PO) (NCT02589457)
  • 01 Oct 2015 Phase-I clinical trials in Hepatitis B treatment (In volunteers) in South Korea (PO) (NCT02589457)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top